Advertisement

Can We Cure Genetic Disorders?

  • Leon E. Rosenberg

Abstract

The question posed in this chapter—namely, “Can we cure genetic disorders?”—is straightforward. The answer is anything but simple, the best answer, in fact, being “Yes, no, and maybe.” If cure is defined as dictionaries define it, (that is, “to restore health,” or “to treat successfully,” or “to succeed with a course of medical treatment”), then current approaches to some genetic disorders qualify. For instance, lifelong restriction of dietary phenylalanine in a neonate with classical phenylketonuria is likely “to restore health” and “to succeed with a course of medical treatment.” Treatment of Wilson’s disease with D-penicillamine and of congenital adrenal hyperplasia with adrenal steroid hormones and of diabetes mellitus with insulin are other examples of successful medical treatments of genetic disorders. But I contend that we ordinarily reserve the word cure for those situations in which the cause of the disorder is eliminated and treatment can be discontinued without relapse (as in the cure of pneumococcal pneumonia with penicillin or of appendicitis by appendectomy). Given this more restrictive definition, the only genetic disorders that we currently cure are those that can be managed surgically (e.g., the correction of cleft palate, the repair of a congenital heart defect, or colectomy for familial polyposis of the colon). Even in these instances, the primary cause of the disorder (i.e., the genetic factors or mutations) has not been addressed. In truth, if we use elimination of the mutant gene as the criterion defining the cure of any genetic disorder, we will never cure any of them because new mutations are occurring all the time, and because I cannot foresee being able to replace defective genes by normal ones in all cells of an affected patient— regardless of how sophisticated we become in our ability to understand and manipulate DNA.

Keywords

Gene Therapy Osteogenesis Imperfecta Fabry Disease Congenital Adrenal Hyperplasia Chronic Granulomatous Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    O’Reilly, R. J., Brochstein, J., Dinsmore, R., and Kirkpatric, D., Marrow transplantation for congenital disorders, Seminars in Hematology 21:188–221 (1984).PubMedGoogle Scholar
  2. 2.
    Hirschhorn, R., Treatment of genetic diseases by allotransplantation. In Desnick, R. J. (ed.), Enzyme Therapy in Genetic Diseases:2, Vol. XVI, No. 1. Birth Defects: Original Article Series ,New York: Alan R. Liss, 1980:429–444.Google Scholar
  3. 3.
    Shows, T. B., The human molecular map of cloned genes and DNA polymorphisms. In Banbury Report 14, Recombinant DNA Applications to Human Disease (C. T. Caskey, and R. L. White, eds.), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1983).Google Scholar
  4. 4.
    Williamson, B., Gene therapy, Nature 298:416–418 (1982).Google Scholar
  5. 5.
    Anderson, W. F., Prospects for human gene therapy, Science 226:401–409 (1984).PubMedCrossRefGoogle Scholar
  6. 6.
    Friedmann, T., in Gene Therapy: Fact and Fiction ,Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1983).Google Scholar
  7. 7.
    Rifkin, J., in Algeny. Viking, New York (1983).Google Scholar
  8. 8.
    Rubin, G. M., and Spradling, A. C, Genetic transformation of Drosophila with transposable element vectors, Science 218:348–353 (1982).PubMedCrossRefGoogle Scholar
  9. 9.
    Hammer, R. E., Palmiter, R. D., and Brinster, R. L., Partial correction of murine hereditary growth disorder by germ-line incorporation of a new gene, Nature 311:65–67 (1984).PubMedCrossRefGoogle Scholar
  10. 10.
    Weisberg, R. A., and Leder, P., Fundamentals of molecular genetics. In The Metabolic Basis of Inherited Disease (5th ed.), (J. B. Stanbury, J. B. Wyngaarden, D. S. Fredrickson, J. L. Goldstein, and M. S. Brown, eds.) McGraw-Hill, New York (1983).Google Scholar
  11. 11.
    Williams, D. A., Lemischka, I. R., Nathan, D. G., and Mulligan, R. C, Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse, Nature 310:476–480 (1984).PubMedCrossRefGoogle Scholar
  12. 12.
    Miller, A. D., Ong, E. S., Rosenfeld, M. G., Verma, I. M., and Evans, R. M., Infectious and selectable retrovirus containing an inducible rat growth hormone minigene, Science 225:993–8 (1984).PubMedCrossRefGoogle Scholar
  13. 13.
    Cline, M. J., Genetic engineering of mammalian cells: Its potential application to genetic diseases of man, /. Lab. Clin. Med. 99:299–308 (1982).Google Scholar
  14. 14.
    Schnieke, A., Harbers, K., and Jaenisch, R., Embryonic lethal mutation in mice induced by retrovirus insertion into the l(I) collagen gene, Nature 304:315–20 (1983).PubMedCrossRefGoogle Scholar
  15. 15.
    Wagner, E. F., Covarrubias, L., Stewart, T. A., and Mintz, B., Prenatal lethalities in mice homozygous for human growth hormone gene sequences integrated in the germ line, Cell 35:647–55 (1983).PubMedCrossRefGoogle Scholar
  16. 16.
    President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Biomedical and Behavioral Research, in Splicing Life ,Government Printing Office, Washington, DC, Stock Number 83-600500 (1982).Google Scholar

Copyright information

© Aubrey Milunsky and George J. Annas 1985

Authors and Affiliations

  • Leon E. Rosenberg
    • 1
  1. 1.Department of Human GeneticsYale University School of MedicineNew HavenUSA

Personalised recommendations